Dose-Response Relationship, Drug
"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the dose of an administered drug and the response of the organism to the drug.
| Descriptor ID |
D004305
|
| MeSH Number(s) |
G07.690.773.875 G07.690.936.500
|
| Concept/Terms |
Dose-Response Relationship, Drug- Dose-Response Relationship, Drug
- Dose-Response Relationships, Drug
- Drug Dose-Response Relationship
- Drug Dose-Response Relationships
- Relationship, Drug Dose-Response
- Relationships, Drug Dose-Response
- Dose Response Relationship, Drug
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".
This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 4 | 4 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 13 | 13 |
| 2003 | 0 | 13 | 13 |
| 2004 | 0 | 10 | 10 |
| 2005 | 0 | 12 | 12 |
| 2006 | 0 | 21 | 21 |
| 2007 | 0 | 14 | 14 |
| 2008 | 0 | 7 | 7 |
| 2009 | 0 | 17 | 17 |
| 2010 | 0 | 16 | 16 |
| 2011 | 0 | 12 | 12 |
| 2012 | 0 | 13 | 13 |
| 2013 | 0 | 14 | 14 |
| 2014 | 0 | 16 | 16 |
| 2015 | 0 | 18 | 18 |
| 2016 | 0 | 23 | 23 |
| 2017 | 1 | 424 | 425 |
| 2018 | 4 | 333 | 337 |
| 2019 | 0 | 124 | 124 |
| 2020 | 1 | 56 | 57 |
| 2021 | 0 | 42 | 42 |
To return to the timeline, click here.
Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.
-
Drug delivery of amoxicillin molecule as a suggested treatment for covid-19 implementing functionalized mesoporous SBA-15 with aminopropyl groups. Drug Deliv. 2021 Dec; 28(1):856-864.
-
Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg Microbes Infect. 2021 Dec; 10(1):810-821.
-
Study on mechanism of matrine in treatment of COVID-19 combined with liver injury by network pharmacology and molecular docking technology. Drug Deliv. 2021 Dec; 28(1):325-342.
-
Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies. Transplantation. 2021 11 01; 105(11):e234-e243.
-
First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19. Clin Pharmacol Ther. 2021 12; 110(6):1467-1477.
-
DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors. Proc Natl Acad Sci U S A. 2021 09 07; 118(36).
-
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. Proc Natl Acad Sci U S A. 2021 09 07; 118(36).
-
Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial. JAMA Intern Med. 2021 09 01; 181(9):1241-1243.
-
Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19. Clin Transl Sci. 2021 11; 14(6):2556-2565.
-
Inhibiting SARS-CoV-2 infection in vitro by suppressing its receptor, angiotensin-converting enzyme 2, via aryl-hydrocarbon receptor signal. Sci Rep. 2021 08 17; 11(1):16629.